| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4756430
Max Phase: Preclinical
Molecular Formula: C26H30N4O5
Molecular Weight: 478.55
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: COC(=O)[C@@H]1[C@H]2C[C@@H]3N(CC[C@@]34C(=O)N(c3cncc(OC)n3)c3ccccc34)C[C@@H]2CC[C@@H]1O
Standard InChI: InChI=1S/C26H30N4O5/c1-34-22-13-27-12-21(28-22)30-18-6-4-3-5-17(18)26(25(30)33)9-10-29-14-15-7-8-19(31)23(24(32)35-2)16(15)11-20(26)29/h3-6,12-13,15-16,19-20,23,31H,7-11,14H2,1-2H3/t15-,16-,19-,20-,23+,26-/m0/s1
Standard InChI Key: VAYMHKVKBAFQNT-IIKGDYKCSA-N
Associated Targets(Human)
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CCR3 Tchem C-C chemokine receptor type 3 (1666 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CCR8 Tchem C-C chemokine receptor type 8 (339 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CX3CR1 Tchem C-X3-C chemokine receptor 1 (1686 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CXCR4 Tclin C-X-C chemokine receptor type 4 (3338 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
FSHR Tclin Follicle stimulating hormone receptor (234 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
OXTR Tclin Oxytocin receptor (1962 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PRLHR Tchem Prolactin-releasing peptide receptor (450 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 478.55 | Molecular Weight (Monoisotopic): 478.2216 | AlogP: 2.06 | #Rotatable Bonds: 3 |
| Polar Surface Area: 105.09 | Molecular Species: BASE | HBA: 8 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 10.36 | CX LogP: 1.37 | CX LogD: -1.48 |
| Aromatic Rings: 2 | Heavy Atoms: 35 | QED Weighted: 0.67 | Np Likeness Score: 0.72 |
References
| 1. Paciaroni NG,Norwood VM,Ratnayake R,Luesch H,Huigens RW. (2020) Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets., 28 (14): [PMID:32616180] [10.1016/j.bmc.2020.115546] |
Source
Source(1):